Применение эверолимуса после трансплантации печени в реальной клинической практике по данным одного центра
Аннотация
Ключевые слова
Об авторах
О. А. ГерасимоваРоссия
Д. А. Гранов
Россия
Ф. К. Жеребцов
Россия
Список литературы
1. Bilbao I, Dopazo C, Lazaro J, Castells L, Caralt M, Sapisochin G et al. Multiple indications for everolimus after liver transplantation in current clinical practice. World J. Transplant. 2014 June 24; 4 (2): 122–132. PMID: 25032101. doi: 10.5500/wjt.v4.i2.122.
2. Fortin MC, Raymond MA, Madore F, Fugère JA, Pâ quet M, St-Louis G et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am. J. Transplant. 2004; 4: 946–952. PMID: 15147429. doi: 10.1111/j.1600-6143.2004.00428.x.
3. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 2003; 349: 847–858. PMID: 12944570. doi: 10.1056/NEJMoa022171.
4. Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl. Int. 2007; 20: 27–36. PMID: 17181650. doi: 10.1111/j.1432-2277.2006.00414.x.
5. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am. J. Transplant. 2013; 13: 1734–1745. PMID: 23714399. doi: 10.1111/ajt.12280.
6. Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997; 64: 36–42. PMID: 9233698.
7. Dumont FJ. Everolimus. Novartis. Curr Opin. Investig Drugs. 2001; 2: 1220–1234. PMID: 11717808.
8. Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L et al. Indications and management of everolimus after liver transplantation. Transplant. Proc. 2009; 41: 2172–2176. PMID: 19715864. doi: 10.1016/j.transproceed.2009.06.087.
9. Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B et al. The use of everolimus in pediatric liver transplant recipients: first experience in a single center. Pediatr. Transplant. 2011; 15: 510–514. PMID: 21696525. doi:10.1111/j.1399-3046.2011.01515.
10. Saliba F, Dharancy S, Lorho R, Conti F, Radenne S et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011; 17 (8): 905–913. doi: 10.1002/lt.22292. PMID: 21384525.
11. Masetti M, Rompianesi G, Montalti R, Romano A, Spaggiari M, Ballarin R et al. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results. Transplant. Proc. 2008; 40: 1947–1949. PMID: 18675097. doi: 10.1016/j.transproceed.2008.05.068.
12. Schrader J, Sterneck M, Klose H, Lohse AW, Nashan B, Fischer L. Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options. Transpl. Int. 2010; 23: 110–113. PMID: 19497063. doi: 10.1111/j.1432-2277.2009.00900.
13. Герасимова ОА, Жеребцов ФК, Филиппенко МО, Гранов ДА. Первый опыт применения эверолимуса после трансплантации трупной печени. Вестник трансплантологии и искусственных органов. 2014; 16: 120. Gerasimova JA, Zherabtsov FK, Filippenko MO, Granov DA. Perviy opyt primenenia everolimusa posle transpalantacii trypnoy pecheni. Vestnik transplantologii i iskusstvennych organov. 2014; 16: 120.
14. EASL Clinical Practice Guidelines: Liver Transplantation. J. Hepatol. 2016; 64 (2): 433–485. doi: 10.1016/j.jhep.2015.10.006.
15. Gastroagudin JF, Molina E, Romero R, Otero E, Tomé S, Varo E. Improvement of renal function after from a calcineurini inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009; 15: 1792–1797. PMID: 19938140. doi: 10.1002/lt.21920.
16. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009; 15: 1262–1269. PMID: 19790150. doi: 10.1002/lt.21827.
17. Fisher L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation – PROTECT. Am. J. Transplant. 2012; 12: 1855–1865. doi: 10.1111/j.1600-6143.2012.04049.x. PMID: 22494671.
18. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am. J. Transplant. 2014; 14: 701–710. PMID: 24502384. doi: 10.1111/ajt.12615.
19. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am. J. Transplant. 2012; 12: 3008–3020. doi: 10.1111/j.1600-6143.2012.04212.x. PMID: 22882750.
20. Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: A multicenter, randomized trial. Am. J. Transplant. 2017; 30. doi: 10.1111/ajt.14212. [Epub ahead of print] PubMed PMID: 28133906.
21. Willamil FG, Gadano AC, Zingale F, Perez R, Gil O, Yantorno S et al. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcinerin inhibitors. Liver Int. 2014; 10: 1513–1521. doi: 10.1111/liv.12416. PMID: 25453134.
22. Saliba F, Nevens F. Progression of liver fibrosis in HCVpositive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen. Liver Int. 2015; 38: 373–374. PMID: 25207429. doi: 10.1111/tri.12449.
23. De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R et al. Use of everolimus in liver transplantation: Recommendations From a Working Group. Transplantation. 2017; 101 (2): 239–251. Published online 2016 Jul 28. doi: 10.1097/TP.0000000000001438. PMID: 27495768.
Рецензия
Для цитирования:
Герасимова О.А., Гранов Д.А., Жеребцов Ф.К. Применение эверолимуса после трансплантации печени в реальной клинической практике по данным одного центра. Вестник трансплантологии и искусственных органов. 2017;19(2):34-40. https://doi.org/10.15825/1995-1191-2017-2-34-40
For citation:
Gerasimova O.A., Granov D.A., Zherebtsov F.K. Everolimus in clinical practice after liver transplantation: a single-center experience. Russian Journal of Transplantology and Artificial Organs. 2017;19(2):34-40. (In Russ.) https://doi.org/10.15825/1995-1191-2017-2-34-40